Monte Rosa Therapeutics, Inc. (GLUE)

Monte Rosa Therapeutics, Inc. is trading at $10.23, up 3.96% on the session. The 50 day average sits at $13.48 and the 200 day at $18.00, which puts the stock in a downtrend. RSI is at 31.3, which reads as weak, and MACD is bullish crossover. Volume is above average.

The nearest support is around $9.68 with resistance near $12.26, so that band frames the current range. Average daily movement is roughly $0.70, or about 6.8% of the share price, which is what any stop placement has to allow for. The overall health score of 30 out of 100 combines a trend score of 0, momentum of 44 and a risk score of 58.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.